AMBROSETTI, Achille
 Distribuzione geografica
Continente #
EU - Europa 9.477
NA - Nord America 8.977
AS - Asia 5.519
SA - Sud America 763
AF - Africa 100
OC - Oceania 33
Continente sconosciuto - Info sul continente non disponibili 10
AN - Antartide 1
Totale 24.880
Nazione #
US - Stati Uniti d'America 8.851
RU - Federazione Russa 2.984
GB - Regno Unito 2.603
SG - Singapore 2.173
CN - Cina 2.042
DE - Germania 756
IT - Italia 735
BR - Brasile 644
SE - Svezia 619
FR - Francia 517
HK - Hong Kong 447
FI - Finlandia 423
IE - Irlanda 416
VN - Vietnam 322
UA - Ucraina 161
KR - Corea 107
IN - India 80
CA - Canada 65
TR - Turchia 60
AR - Argentina 52
ID - Indonesia 47
BE - Belgio 38
JP - Giappone 38
PL - Polonia 38
BD - Bangladesh 37
MX - Messico 33
AU - Australia 32
IR - Iran 31
ZA - Sudafrica 30
NL - Olanda 29
ES - Italia 27
IQ - Iraq 22
CZ - Repubblica Ceca 21
AT - Austria 20
EC - Ecuador 16
RO - Romania 14
CO - Colombia 13
UZ - Uzbekistan 12
NP - Nepal 11
AE - Emirati Arabi Uniti 10
GR - Grecia 10
MA - Marocco 10
PK - Pakistan 10
DZ - Algeria 9
EU - Europa 9
PE - Perù 9
SA - Arabia Saudita 9
VE - Venezuela 9
AZ - Azerbaigian 8
EG - Egitto 8
LT - Lituania 8
TH - Thailandia 8
TN - Tunisia 8
CH - Svizzera 7
CL - Cile 7
ET - Etiopia 7
GH - Ghana 7
LV - Lettonia 7
PY - Paraguay 7
DK - Danimarca 5
KZ - Kazakistan 5
NO - Norvegia 5
PA - Panama 5
SY - Repubblica araba siriana 5
AL - Albania 4
BG - Bulgaria 4
CG - Congo 4
DO - Repubblica Dominicana 4
LB - Libano 4
LK - Sri Lanka 4
NI - Nicaragua 4
PT - Portogallo 4
BO - Bolivia 3
CM - Camerun 3
CR - Costa Rica 3
EE - Estonia 3
HU - Ungheria 3
JM - Giamaica 3
KE - Kenya 3
KG - Kirghizistan 3
LU - Lussemburgo 3
MY - Malesia 3
PH - Filippine 3
UY - Uruguay 3
AM - Armenia 2
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BY - Bielorussia 2
CI - Costa d'Avorio 2
GE - Georgia 2
JO - Giordania 2
MD - Moldavia 2
OM - Oman 2
PS - Palestinian Territory 2
SI - Slovenia 2
SN - Senegal 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
AO - Angola 1
AQ - Antartide 1
Totale 24.856
Città #
Southend 2.234
Jacksonville 1.283
Chandler 1.029
Singapore 1.018
Moscow 918
Woodbridge 823
Dallas 781
Ashburn 633
Ann Arbor 540
Hong Kong 443
Dublin 415
Houston 362
Beijing 291
Wilmington 215
Los Angeles 196
Jinan 193
Lawrence 179
Princeton 179
Buffalo 170
Nanjing 165
The Dalles 161
Shenyang 156
New York 143
Hebei 102
Boardman 100
Ho Chi Minh City 95
Helsinki 82
Columbus 74
Tianjin 74
São Paulo 71
Sindelfingen 70
Zhengzhou 68
Munich 66
Milan 65
Verona 63
Hanoi 59
Hangzhou 58
Changsha 57
Seattle 57
Haikou 56
Taizhou 55
Nanchang 54
Jiaxing 49
Guangzhou 46
Philadelphia 46
Dong Ket 45
Ningbo 45
Santa Clara 42
Falls Church 41
Rome 40
Council Bluffs 39
Fairfield 39
Turku 37
Brussels 35
Cambridge 35
Jakarta 34
Redondo Beach 34
Taiyuan 31
Norwalk 30
Tokyo 29
Lanzhou 28
Seoul 28
Montreal 27
Warsaw 27
Fuzhou 25
Lancaster 25
London 25
Dearborn 24
Brooklyn 23
Frankfurt am Main 23
Bologna 22
Redwood City 22
Redmond 21
Stockholm 21
Toronto 20
Belo Horizonte 19
Rio de Janeiro 19
Atlanta 18
San Francisco 18
Washington 18
Phoenix 17
Auburn Hills 16
Johannesburg 16
Provo 16
Brno 15
Chennai 15
Düsseldorf 15
Denver 14
Orem 14
Boston 13
Falkenstein 13
Haiphong 13
Perth 13
San Jose 13
Brasília 12
Chicago 12
Nuremberg 12
Vienna 12
Mexico City 11
Poplar 11
Totale 15.276
Nome #
Immunocitologia e immunoistologia delle cellule midollari normali e neoplastiche 418
A simplified immunological approach to the diagnosis of chronic lymphocytic leukaemia and other lymphoproliferative disorders 264
Linfomi del tessuto linfatico associato alle mucose (MALT) delle ghiandole salivari. Descrizione di un caso in un paziente con infezione da virus C dell'epatite e revisione della letteratura 238
Prognostic value of serum markers of established impact on prognosis in relation with ZAP-70 expression in B-CLL patients 222
CAL2 Monoclonal Antibody Is a Rapid and Sensitive Assay for the Detection of Calreticulin Mutations in Essential Thrombocythemia and May Provide Prognostic Informations 222
Acute leukemia and pregnancy. Case report 214
Analisi del riarrangiamento bcr-abl in alcuni pazienti affetti da leucemia mieloide cronica 214
Alpha-interferon activates the natural killer system in patients with hairy cell leukemia 212
Notch signalling drives bone marrow stromal cell-mediated chemoresistance in acute myeloid leukemia 211
Alpha-interferon activated cytotoxic lymphocytes in hairy cell leukemia patients: evaluation of cytotoxic events 210
A proliferation-inducing ligand (APRIL) serum levels predict time to first treatment in patients affected by B-cell chronic lymphocytic leukemia 210
An assessment of chimeric transcript detection in CML patients after bone marrow transplantation 206
Serum levels of soluble interleukin-2 receptor in hairy cell leukaemia: a reliable marker of neoplastic bulk 201
BCR-ABL fusion transcript b2a2 is associated with a higher risk of non-optimal early response in CP-CML patients treated with standard dose imatinib: a study from Gruppo Triveneto LMC. 200
Blood smear, a key diagnostic tool in hematology: Lessons from two cases of acute hemolysis in previously undiagnosed g6pd deficiency 200
Alpha-interferon activates the natural killer system in patients with hairy cell leukemia 198
Absence of TCL1A expression is a useful diagnostic feature in splenic marginal zone lymphoma. 197
The diagnostic value of serum copper levels and other hematochemical parameters in malignancies 194
[The use of betamethasone in polychemotherapy of lymphoproliferative diseases] 190
Anemie iporigenerative ipercromiche e macrocitiche 190
The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia 189
Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia 189
[Liver and spleen involvement in Hodgkin's disease: critical evaluation of diagnostic procedures (author's transl)] 188
Inhibition of Notch signalling overcomes bone marrow stromal-mediated anti-apoptotic and chemoresistance effects in AML. 188
[Clinical and pathological staging of 85 patients with Hodgkin's disease: a clinical contribution (author's transl)] 187
Chronic graft versus host disease is associated with erectile dysfunction in allogeneic hematopoietic stem cell transplant patients: a single-center experience 187
CXCL8/interleukin 8 in B-cell chronic lymphocytic leukemia is up-regulated through the activity of the CXCL12/CXCR4 axis 186
An unusual case of acute leukaemia 182
Predictive factors of stable deep molecular response in chronic myeloid leukemia patients treated with imatinib standard dose: a study from the Gruppo Triveneto LMC. 181
Autoimmune complications are frequent in splenic and nodal marginal zone lymphomas 180
Combination of chemotherapy and radiotherapy improves the cure rate in primary extranodal lymphomas of the head and neck (PLHN) 179
Different suppression of Ph1 positive hemopoiesis induced by intensive chemotherapy in lymphoid and myeloid blast crisis of CML 177
Soluble interleukin-2 receptors in the sera of patients with hairy cell leukemia: relationship with the effect of recombinant alpha-interferon therapy on clinical parameters and natural killer in vitro activity 176
Ceftazidime and amikacin as empiric antibiotic therapy of febrile granulocytopenic patients with hematological malignancies. Report of 171 consecutive episodes 176
Monoterapia empirica con ceftazidime nelle infezioni di pazienti neutropenici affetti da emopatie maligne 174
Leucemie 174
PROGNOSTIC VALUE OF SERUM THYMIDINE KINASE LEVEL AND ZAP-70 EXPRESSION DETECTED BY IMMUNOHISTOCHEMISTRY ON BONE MARROW BIOPSIES IN B-CLL: COMPARATIVE ANALYSIS 174
CAL2 monoclonal antibody is a rapid and sensitive assay for the detection of calreticulin mutations in essential thrombocythemia and may provide prognostic informations 173
Espressione del CD30 ligando sulle cellule di differenti neoplasie ematologiche leucemiche 171
B cells in chronic lymphocytic leukaemia. Comparative analysis of blood and bone marrow 170
Prognostic factors in acute non-lymphocytic leukemia with respect to treatment response 170
Chirurgia e chemioterapia nel trattamento dei linfomi gastrici primitivi: revisione casistica 170
Integrated single cell network profiling data of ERK signaling and mutations of SF3B1 gene refine prognosis in chronic lymphocytic leukemia 170
Folic acid binding protein in chronic granulocytic leukaemia: the effect of methotrexate 168
Predictors of stable deep molecular response in chronic phase chronic myeloid leukemia patients treated with dasatinib or nilotinib after imatinib failure 168
Primary extranodal lymphomas of Waldeyer's ring, stage IE and IIE: Long-term survival after chemotherapy combined with radiotherapy 166
2-chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage III-IV non-Hodgkin's lymphoma [see comments] 166
Postoperative chemotherapy increases the disease-free survival rate in primary gastric lymphomas stage IE and IIE 166
Soluble interleukin-2 receptor in the serum of patients with Hodgkin's Disease: A new biological marker of disease activity 166
CT imaging of primary pancreatic lymphoma: experience from three referral centres for pancreatic diseases 163
Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi 163
Bone marrow transplantation monitoring by DNA analysis 160
Autoimmune cytopenias in chronic lymphocytic leukemia at disease presentation in the modern treatment era: is stage C always stage C? 160
Integration of B-cell receptor-induced ERK1/2 phosphorylation and mutations of SF3B1 gene refines prognosis in treatment naive chronic lymphocytic leukemia 159
Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia 159
CT IMAGING OF PRIMARY PANCREATIC LYMPHOMA 157
the International Extranodal Lymphoma Study group (IELSG). Intravascular lymphoma: clinical presentation, natural history, management, and prognostic factors in a series of 38 cases, with special emphasis on the “cutaneous variant”. 155
A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia 153
Oral itraconazole plus nasal amphotericin B for prophylaxis of invasive aspergillosis in patients with hematological malignancies 153
Mediastinal large-cell lymphoma of B-type, with sclerosis: histopathological and immunohistochemical study of eight cases 152
Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy 151
Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response 151
OFATUMUMAB AND LENALIDOMIDE PREFERENTIALLY INHIBIT B-CELL RECEPTOR SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS WITH MUTATED IGHV 151
Splenectomy for patients with myelofibrosis with myeloid metaplasia: pretreatment variables and outcome prediction 150
Unicentric Castleman's lymphadenopathy presenting with Behcet's syndrome: a case report 149
Terminal transferase expression in relapsed acute myeloid leukaemia 149
Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma. 149
Valutazione del significato della cupremia come indice di attività e come segno precoce di ricaduta nel cancro della mammella e nel morbo di Hodgkin (studio su 270 Casi). 149
Comparison of dasatinib and nilotinib as second-line therapy after imatinib failure in chronic phase chronic myeloid leukemia patients. 149
Use of prothrombin complex concentrate for prophylaxis of bleeding in acquired factor X deficiency associated with light-chain amyloidosis 149
The impact of P53 and P21(waf1) expression on the survival of patients with the germinal center phenotype of diffuse large B-cell lymphoma 149
Transplantation potential of peripheral whole blood primed by VACOP-B chemotherapy plus filgrastim (r-metHuG-CSF) in patients with aggressive non-Hodgkin's lymphoma 148
Regulation of the proliferative potential of cord blood long term culture initiating cells (LTC-IC) by different stromal cell lines: implications for LTC-IC measurement 147
Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin's lymphoma 147
THE COMBINATION OF SERUM THYMIDINE KINASE, B-2-MICROGLOBULIN AND SOLUBLE CD23 AT DIAGNOSIS IS PREDICTIVE FOR PROGRESSION IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA, INDEPENDENTLY FROM ZAP-70 EXPRESSION 146
Molecular “warning” CML patients: a retrospective study of Gruppo Triveneto LMC. 146
Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia 145
Mycobacterial infections preceding hairy-cell leukemia diagnosis. Description of two cases 145
Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas. 145
Detection of normal and malignant megakaryocytes by anti beta-thromboglobulin serum. An immunofluorescence study 144
Clinical value of PCR in diagnosis and follow-up of leukaemia and lymphoma: report of the Third Workshop of the Molecular Biology/BMT Study Group 144
Multiple large osteolytic lesions in a patient with systemic mastocytosis: a challenging diagnosis 144
Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease 143
Mediastinal large-B-cell lymphoma with sclerosis: a clinical study of 21 patients 142
Short-term, intensive chemotherapy regimen is equally effective in Burkitt lymphoma (BL) and in the novel WHO 2008 entity “B-cell lymphoma intermediate between DLBCL and BL". 140
Distribution and heterogeneity of cells detected by HNK-1 monoclonal antibody in blood and tissues in normal, reactive and neoplastic conditions 139
Serum levels of soluble CD30 improve international prognostic score in predicting the outcome of advanced Hodgkin's lymphoma 139
The combination of Serum Thymidine Kinase, Beta-2-Microglobulin and soluble CD23 at diagnosis is predictive for progression in B-cell Chronic Lymphocytic Leukemia, independently from ZAP-70 expression 139
BCR breakpoint subregions and blast crisis lineage in CML patients 138
Pilot study of survival of patients with chronic myeloid leukemia after determination of intracellular folate binding protein (FABP) 137
Epstein-Barr virus DNA load in chronic lymphocytic leukemia is an independent predictor of clinical course and survival 137
Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice 136
Real-life comparison of dasatinib and nilotinib as second-line therapy after imatinib failure for chronic phase CML 133
Soluble interleukin-2 receptor in hairy cell leukemia: A reliable marker of disease 132
Relationship between Daunorubicin dosage delivered during induction therapy and outcome in adult acute lymphoblastic leukemia 131
ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factor. 130
Remission of severe antiphospholipid syndrome associated with non Hodgkin's B-cell lymphoma after combined treatment with Rituximab and chemotherapy 130
Patterns of outcome and prognostic factors in primary large cell lymphoma of the testis in a survey of 373 patients by the International Extranodal Lymphoma Study Grfoup (IELSG). 129
Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients 129
Immunohistologic study of bone marrow involvement in B-chronic lymphocytic leukemia 128
Totale 16.935
Categoria #
all - tutte 77.118
article - articoli 62.389
book - libri 0
conference - conferenze 12.130
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.599
Totale 154.236


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021983 0 0 0 0 0 247 21 138 147 25 265 140
2021/20221.494 144 426 15 113 86 45 33 92 59 39 134 308
2022/20232.990 229 282 292 549 311 705 47 155 314 25 62 19
2023/20241.441 69 143 131 176 157 202 59 104 17 73 196 114
2024/20253.758 265 228 119 623 242 146 186 181 579 194 294 701
2025/20266.515 755 604 862 1.493 2.383 418 0 0 0 0 0 0
Totale 25.061